{
    "root": "315a7228-5483-e869-e063-6294a90a84ae",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Methylphenidate Hydrochloride",
    "value": "20250327",
    "ingredients": [
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "PHOSPHORIC ACID",
            "code": "E4GA8884NN"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SUCCINIC ACID",
            "code": "AB6MNQ6J6L"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "CELLULOSE ACETATE",
            "code": "3J2P07GVB6"
        },
        {
            "name": "POLYETHYLENE OXIDE 200000",
            "code": "11628IH70O"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "POLYETHYLENE OXIDE 5000000",
            "code": "3IG9032SAH"
        },
        {
            "name": "METHYLPHENIDATE HYDROCHLORIDE",
            "code": "4B3SC438HI"
        }
    ],
    "indications": "methylphenidate hydrochloride extended-release tablets indicated treatment attention deficit hyperactivity disorder ( adhd ) children 6 years age older , adolescents , adults age 65 [ ( 14 ) ] .",
    "contraindications": "methylphenidate hydrochloride extended-release tablets taken daily morning swallowed whole aid liquids . methylphenidate hydrochloride extended-release tablets chewed crushed . methylphenidate hydrochloride extended-release tablets may taken without food . ( 2.2 ) children adolescents new methylphenidate , recommended starting 18 mg daily . may increased 18 mg/day weekly intervals exceed 54 mg/day children 72 mg/day adolescents . ( 2.3 ) adult patients new methylphenidate , recommended starting dose 18 36 mg/day . may increased 18 mg/day weekly intervals exceed 72 mg/day adults . ( 2.3 ) patients currently using methylphenidate , dosing based current dose regimen judgment . ( 2.4 )",
    "warningsAndPrecautions": "methylphenidate hydrochloride extended-release tablets , usp available 18 , 27 , 36 , 54 strengths . 18 mg tablets yellow \u201c tl706 \u201d imprinted black ink , 27 mg tablets gray \u201c tl707 \u201d imprinted black ink , 36 mg tablets white \u201c tl708 \u201d imprinted black ink , 54 mg tablets pink \u201c tl709 `` imprinted black ink . tablets supplied : 18 mg . . . . . . . . . . 100-count bottle . . . . . . . . ndc 51407-924-01 27 mg . . . . . . . . . . 100-count bottle . . . . . . . . ndc 51407-925-01 36 mg . . . . . . . . . . 100-count bottle . . . . . . . . ndc 51407-926-01 54 mg . . . . . . . . . . 100-count bottle . . . . . . . . ndc 51407-927-01",
    "adverseReactions": "known hypersensitivity product ( 4.1 ) methylphenidate hydrochloride extended-release tablets patients currently using within 2 weeks using mao inhibitor ( 4.2 )",
    "indications_original": "Methylphenidate hydrochloride extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65\n \n   [see Clinical Studies\n  \n    \u00a0(14)]\n \n   .",
    "contraindications_original": "Methylphenidate hydrochloride extended-release tablets\u00a0should be taken once daily in the morning and swallowed whole with the aid of liquids. Methylphenidate hydrochloride extended-release tablets\u00a0should not be chewed or crushed. Methylphenidate hydrochloride extended-release tablets\u00a0may be taken with or without food. ( 2.2 ) For children and adolescents new to methylphenidate, the recommended starting dosage is 18 mg once daily. Dosage may be increased by 18 mg/day at weekly intervals and should not exceed 54 mg/day in children and 72 mg/day in adolescents. ( 2.3 ) For adult patients new to methylphenidate, the recommended starting dose is 18 or 36 mg/day. Dosage may be increased by 18 mg/day at weekly intervals and should not exceed 72 mg/day for adults. ( 2.3 ) For patients currently using methylphenidate, dosing is based on current dose regimen and clinical judgment. ( 2.4 )",
    "warningsAndPrecautions_original": "Methylphenidate hydrochloride extended-release tablets, USP are available in 18, 27, 36, and 54 strengths. The 18 mg tablets are yellow with \u201cTL706\u201d imprinted in black ink, 27 mg tablets are gray with \u201cTL707\u201d imprinted in black ink, 36 mg tablets are white with \u201cTL708\u201d imprinted in black ink, and 54 mg tablets are pink with \u201cTL709\" imprinted in black ink.\n                  The tablets are supplied:\n                  \n                  18 mg ..........100-count bottle........NDC 51407-924-01\n                  27 mg ..........100-count bottle........NDC 51407-925-01\n                  36 mg ..........100-count bottle........NDC 51407-926-01\n                  54 mg ..........100-count bottle........NDC 51407-927-01",
    "adverseReactions_original": "Known hypersensitivity to the product ( 4.1 ) Do not use methylphenidate hydrochloride extended-release tablets in patients currently using or within 2 weeks of using an MAO inhibitor ( 4.2 )"
}